Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients

Leukemia

Volumn 17, Issue 8, 2003, Pages 1583-1588

  Wang, B ^a   Relling, M V ^a,b   Storm, M C ^b   Woo, M H ^a   Ribeiro, R ^a   Pui, C H ^a   Hak, L J ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Antiasparaginase antibody; Cross reactivity; L asparaginase

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BACTERIAL ENZYME; BACTERIUM ANTIBODY; CROSS REACTING ANTIBODY; MACROGOL;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLERGIC REACTION; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERWINIA; ESCHERICHIA COLI; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; INFANT; MALE; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL;

EID: 0041520550     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403011     Document Type: Article

References (34)

1. Capizzi RL, Bertino JR, Skeel RT, Creasey WA, Zanes R, Olayon C et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971; 74: 893-901.
2. Asselin BL, Ryan D, Frantz CN, Bernal SD, Leavitt P, Sallan SE et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res 1989; 49: 4363-4368.
3. Asselin BL, Lorenson MY, Whitin JC, Coppola DJ, Kende AS, Blakley RL et al. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res 1991; 51: 6568-6573.
4. Capizzi RL, Bertino JR, Handschumacher RE. L-asparaginase. Ann Rev Med 1970; 21: 433-444.
5. Capizzi RL. Asparaginase revisited. Leukemia Lymphoma 1993; 19(Suppl): 147-150.
6. Capizzi RL, Holcenberg JS. Asparaginase. In: Holland JF et al. Cancer Medicine, 3rd edn, Vol. XVI-9. Philadelphia: Lea & Febiger, 1993, pp 796-806.
7. Evans WE, Tsiatis A, Rivera G, Murphy SB, Dahl G.V. Denison M et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982; 49: 1378-1383.
8. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11: 1780-1786.
9. Asselin BL. The three-asparaginases: comparative pharmacology and optimal use in childhood leukemia. In: Kaspers et al. Drug Resistance in Leukemia and Lymphoma, Vol. III. New York: Kluwer Academic/Plenum Publishers, 1999, pp 621-629.
10. Peterson RG, Hanschumacher RE, Mitchell MS. Immunological responses to L-asparaginase. J Clin Invest 1971; 50: 1080-1090.
11. Keating MJ, Holmes R, Lerner S, Ho DH. L-asparaginase and PEG asparaginase - past, present, and future. Leukemia Lymphoma 1993; 10: 153-157.
12. Killander D, Dohlwitz A, Engstedt L, Franzen S, Gahrton G, Gullbring B et al. Hypersensitivity reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976; 37: 220-228.
13. Cheung N-KV, Chau IY, Coccia PF. Antibody response to Escherichia Coli L-asparaginase: prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol/Oncol 1986; 8: 99-104.
14. Woo MH, Hak LJ, Storm MC, Evans WE, Sandlund JT, Rivera GK et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998; 12: 1527-1533.
15. Park YK, Abuchowski A, Davis S, Davis F. Pharmacology of Escherichia Coli- L-asparaginase polyethylene glycol adduct. Anticancer Res 1981; 1: 373-376.
16. Yoshimoto T, Nishimura H, Saito Y, Sakurai K, Kamisaki Y, Wada H et al. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn J Cancer Res (Gann) 1986; 77: 1264-1270.
17. Billett AL, Carls A, Gelber RD, Sallan SE. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 1992; 70: 201-206.
18. The Medical Letter. Pegaspargase for acute lymphoblastic leukemia. Med Lett Drugs Ther 1995; 37: 23-24.
19. Stone DH, DiPiro C, Davis CP, Meyer CF, Wray BB. Hypersensitivity reactions to Escherichia coli-derived polyethylene glycolated-asparaginase associated with subsequent immediate skin test reactivity to E. coli-derived granulocyte colony-stimulating factor. J Allergy Clin Immunol 1998; 101: 429-431.
20. Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 1525-1532.
21. Oettgen HF, Stephenson PA, Schwartz MK, Leeper RD, Tallal L, Tan CC et al. Toxicity of E. Coli L-asparaginase in man. Cancer 1970; 25: 253-278.
22. Oncaspar prescribing information. Physicians' Desk Reference®, Montvale, NJ: Tomson PDR, 2002, pp 756-758.
23. Holle LM. Pegaspargase: an alternative? Ann Pharmacotherapy 1997; 31: 616-624.
24. Wada H, Imamura I, Sako M, Katagiri S, Tarui S, Nishimura H et al. Antitumor enzyme: polyethylene glycol-modified asparaginase. Ann NY Acad Sci 1990; 613: 95-108.
25. Ettingger LJ, Kurtzberg J, Voute PA, Jurgens H, Halpern SL. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 1995; 75: 1176-1181.
26. Pui C-H, Relling MV, Behm FG, Hancock ML, Boyett JM, Raimondi SC et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995; 9: 1680-1684.
27. Wang B, Hak LJ, Relling MV, Pui C-H, Woo MH, Storm MC. ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. J Immunol Methods 2000; 237: 75-83.
28. Roitt I, Brostoff J, Male D. Immunology: Antigen Recognition, 3rd edn. London-New York: Gower Medical Publishing, 1996, p 7.4.
29. Ho DH, Brown NS, Yen A, Holmes R, Keating M, Abuchowski A et al. Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos 1986; 14: 349-352.
30. Asselin BL, Kreissman S, Coppola DJ, Bernal SD, Leavitt PR, Gelber RD et al. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1999; 21: 6-12.
31. Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study. Blood 2000; 96: 1709-1715.
32. Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P et al. Comparision of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer, Children's Leukemia Group phase 3 trail. Blood 2002; 15: 2734-2739.
33. Boo J, Weber G, Ahlke E, Schulze-Westhoff P, Nowak-Dottl U, Wurthwein G et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Euro J Cancer 1996; 32: 1544-1550.
34. Ettinger LJ. Asparaginases: where do we go from here? J Pediatr Hematol Oncol 1999; 21: 3-5.